Education
About Us
Working with TipRanks
Follow Us
Alphatec (ATEC)
NASDAQ:ATEC
ATEC Stock Chart & Stats
$14.85
$0.31(3.32%)
At close: 4:00 PM EST
$14.85
$0.31(3.32%)
Day’s Range― - ―
52-Week Range$8.81 - $23.29
Previous CloseN/A
Volume519.80K
Average Volume (3M)2.94M
Market Cap
$2.27B
Enterprise Value$2.64B
Total Cash (Recent Filing)$155.74M
Total Debt (Recent Filing)$591.15M
Price to Earnings (P/E)―
Beta0.77
Next Earnings
Feb 24, 2026EPS Estimate
0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.03
Shares Outstanding148,550,190
10 Day Avg. Volume3,229,632
30 Day Avg. Volume2,940,285
Financial Highlights & Ratios
PEG Ratio0.30
Price to Book (P/B)139.10
Price to Sales (P/S)2.15
P/FCF Ratio-9.52
Enterprise Value/Market Cap1.16
Enterprise Value/Revenue3.62
Enterprise Value/Gross Profit5.24
Enterprise Value/Ebitda-50.53
Forecast
1Y Price Target
$24.40Price Target Upside64.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)0.21
Revenue Forecast (FY)$888.14M
Bulls Say, Bears Say
Bulls Say
Commercial AdoptionGrowing surgeon adoption of the company's procedural, implant, and enabling technologies can drive higher procedure volumes and increase revenue per surgeon as clinical use broadens.
Partnerships And PipelineExclusive U.S. distribution rights for a next-generation spinal biologic expand procedural options and could make the company more competitive with surgeons focused on biologic solutions.
Upcoming Product LaunchesPlanned rollouts of lateral and deformity solutions along with a robotic navigation system create tangible product catalysts that can accelerate market share gains and support revenue growth.
Bears Say
Execution And Regulatory RiskCommercial, partnership, regulatory, and financial execution risks could impede strategy execution and increase uncertainty around achieving long-range targets.
Guidance And Market ExpectationsConservative management guidance may temper upside expectations and reduce investor confidence in near-term growth projections.
Procedure Mix And Surgical GrowthModeration in surgical growth coupled with a decline in revenue per surgery suggests a shift toward simpler procedures that could weaken average selling prices and slow top-line momentum.
Alphatec Holdings News
ATEC FAQ
What was Alphatec’s price range in the past 12 months?
Alphatec lowest stock price was $8.81 and its highest was $23.29 in the past 12 months.
What is Alphatec’s market cap?
Alphatec’s market cap is $2.27B.
When is Alphatec’s upcoming earnings report date?
Alphatec’s upcoming earnings report date is Feb 24, 2026 which is in 24 days.
How were Alphatec’s earnings last quarter?
Alphatec released its earnings results on Oct 30, 2025. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of -$0.031 by $0.061.
Is Alphatec overvalued?
According to Wall Street analysts Alphatec’s price is currently Undervalued.
Does Alphatec pay dividends?
Alphatec does not currently pay dividends.
What is Alphatec’s EPS estimate?
Alphatec’s EPS estimate is 0.04.
How many shares outstanding does Alphatec have?
Alphatec has 148,550,190 shares outstanding.
What happened to Alphatec’s price movement after its last earnings report?
Alphatec reported an EPS of $0.03 in its last earnings report, beating expectations of -$0.031. Following the earnings report the stock price went up 16.289%.
Which hedge fund is a major shareholder of Alphatec?
Currently, no hedge funds are holding shares in ATEC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alphatec Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$24.40 (64.31% Upside)
$24.40 (64.31% Upside)
Blogger Sentiment
Bullish
ATEC Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 62.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $75.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 2.3%
Last 30 Days ▼ 2.3%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
26.21%
12-Months-Change
Fundamentals
Return on Equity
-540.40%
Trailing 12-Months
Asset Growth
5.54%
Trailing 12-Months
Company Description
Alphatec
Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders. The company offers SafeOp Neural InformatiX System, an Alpha InformatiX product platform designed to reduce the risk of intraoperative nerve injury; Sigma transforaminal lumbar interbody fusion pedicle-based access system that provides direct visualization of anatomical landmarks; Sigma PTP Access and Patient Positioning System; squadron lateral retractor designed to maximize patient outcomes; Invictus Spinal Fixation System, a thoracolumbar fixation system to treat a range of pathologies; and Invictus MIS SingleStep System that provides minimally invasive pedicle screw placement. It also provides Invictus Modular Fixation Systems designed to increase adaptability with the power of screw modularity; OsseoScrew system to restore the integrity of the spinal column; Arsenal spinal fixation system, a comprehensive thoracolumbar fixation platform to fix a range of degenerative to deformity pathologies and surgical procedures; Aspida Anterior Lumbar Plating System, a fixation system for anterior lumbar interbody fusion; AMP Anti-Migration Plate; OCT Spinal Fixation System; trestle luxe anterior cervical plate system; and Insignia Anterior Cervical Plate System. In addition, the company offers IdentiTi Porous Ti, Transcend Lateral, and Battalion Posterior Interbody Implants; and biologics consisting of Cervical Structural Allograft Spacers, 3D ProFuse Demineralized Bone Scaffold, Neocore Osteoconductive Matrix, Alphagraft Demineralized and Cellular Bone Matrix, and Amnioshield Amniotic Tissue Barrier, as well as EOS imaging products. It sells its products through a network of independent distributors and direct sales representatives in the United States. The company was founded in 1990 and is headquartered in Carlsbad, California.
ATEC Company Deck
ATEC Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
ATEC demonstrated strong financial performance with significant revenue growth, increased surgeon adoption, and positive free cash flow. The company raised its full-year guidance and achieved record adjusted EBITDA. While there are some challenges related to tariff impacts and market disruption, the overall performance and strategic positioning indicate a positive outlook.View all ATEC earnings summariesATEC Stock 12 Month Forecast
Average Price Target
$24.40
▲(64.31% Upside)
Technical Analysis
Ownership Overview
39.71% Insiders
14.78% Mutual Funds
1.27% Other Institutional Investors
31.40% Public Companies and
Individual Investors